NCT07208318 Restructuring the Alpha-Gamma Code in Aging Vision
| NCT ID | NCT07208318 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Boston University Charles River Campus |
| Condition | Aging |
| Study Type | INTERVENTIONAL |
| Enrollment | 240 participants |
| Start Date | 2026-04-02 |
| Primary Completion | 2030-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 240 participants in total. It began in 2026-04-02 with a primary completion date of 2030-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Tests whether age-related visual deficits arise from disrupted alpha-gamma coupling in visual cortex (V1) and MT. Uses fMRI, source-resolved HD-EEG, and personalized complex-waveform HD-tACS to (1) quantify aging effects on phase-amplitude coupling, (2) drive PAC into a preferred "gamma-at-alpha-troughs" state, and (3) bidirectionally change perception by aligning gamma to alpha troughs vs peaks. Two five-day, double-blind, sham-controlled studies (n=120 each) target contrast sensitivity (V1) and 3D shape-from-motion (MT), aiming for mechanistic insight and remediation in older adults with implications for ADRD.
Eligibility Criteria
Inclusion Criteria: * 18+ years of age or older * normal or corrected-to-normal visual acuity, color vision, and stereo vision Exclusion Criteria: * not pregnant, * no metal implants in head, * no implanted electronic devices, * no history of neurological problems or head injury, * no skin sensitivity, * no claustrophobia, * no dementia (normal Mini Mental State Examination between 24-30; Montreal Cognitive Assessment \> 25) * no depression (normal Beck Depression Inventory II \<13; Geriatric Depression Scale \< 10) * no ophthalmological diseases (e.g., strabismus, glaucoma, cataract, macular degeneration) * no history of psychosis * no cognitive deficits (MMSE score\>24; MoCA\>25) * cannot be taking any psychoactive medication.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07208318 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Aging. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07208318 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07208318 currently recruiting?
Yes, NCT07208318 is actively recruiting participants. Contact the research team at rmgr@bu.edu for enrollment information.
Where is the NCT07208318 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT07208318 clinical trial?
NCT07208318 is sponsored by Boston University Charles River Campus. The trial plans to enroll 240 participants.